Appendix

Basic science

Equations

1 atomic mass unit (amu) = 1/12 the mass of a carbon-12 atom

Maximum number of electrons in a shell = 2n2 (n = shell number)

Kinetic energy = ½mv2 (m = mass; v = velocity)

Frequency = 1 / T (T = time between successive peaks in seconds)

Velocity (c, ms-1) = fλ (f = frequency; λ = wavelength)

Intensity (E) = hf (h = Planck's constant; f = frequency)

Intensity (E) = h/λ

Intensity ∝ 1 / d2 (d = distance)

Miscellaneous

 Relative mass Charge Symbol Neutron 1 0 n Proton 1 +1 p Electron 0 (1/2000) -1 e-

1 Becquerel (Bq) = 1 transformation per second

X-ray imaging

Equations

Heat (J) = kVe x mAs = w x kVp x mAs (kVe = effective kV, w = waveform, kVp = peak kV, mAs = current per second)

Temperature rise = energy applied / heat capacity

Compton scatter ∝ density / energy

Photoelectric LAC ∝ ρZ3 / E3 (ρ = density, Z = atomic number, E = energy)

Compton LAC = ρ / E

Factor of reduction = 2HVL (HVL = half value layer)

Linear attenuation coefficient (LAC, cm-1) = 0.693 / HVL

Mass attenuation coefficient (MAC, cm2g-1) = LAC / density

Image plate (IP) = barium fluorohalide activated with divalent europium ions. 0.3 mm

Red laser beam for read out

Light released in blue part of spectrum

Speed = 2000 / X (X = dose incident on IP)

Detective quantum efficiency (DQE) = SNR2out / SNR2in (SNR = signal to noise ratio)

• 0.25 for standard IP
• 0.12 for high resolution IP

Indirect DR

Scintillator layer = 500 μm layer of caesium iodide with thallium (CsI:Tl)

X-ray photon → ~3000 light photons in green spectrum

Matrix = amorphous silicon layer doped with hydrogen (a-Si:H)

Fill factor = sensitive area / overall area

Direct DR

Photoconductor = amorphous selenium (a-Se)

Mammography

Maximum compression = 200 N (normal = 100-150 N)

Target/filter:

• General use: MoMo
• Dense breasts: MoRh or RhRh

Broad focal spot = 0.3 mm

Fine focal spot = 0.1 - 0.15 mm

Focus-to-film distance = 65-66 cm

Fluoroscopy

Equipment

II window made of aluminium of titanium foil

Input phosphor:

• Sodium activated caesium iodide (CsI:Na)
• 400-500 μm thick,
• Produces light photons in blue spectrum

Photocathode:

• Antimony caesium (SbCs3)

Output screen:

• Silver-activated zinc cadmium sulphide (ZnCdS:Ag)
• 25-35 in diameter, few micrometres thick
Equations:

Gbrightness = Gminification x Gflux (Gminification = minification gain; Gflux = flux gain)

Gminification = (Dinput / Doutput)2 (Dinput = diameter of input screen; Doutput = diameter of output screen)

Gx = L / X' (Gx = image intensifier conversion factor; L = luminance of the output; X' = entrance dose rate)

Gminification ~ 100

Gflux ~ 100

Gx ~ 10-30

Elements

Tungsten (W)

• Kα = 59.3 keV
• Kβ = 67.6 keV

Mass number (A) = 184

Atomic number (Z) = 74

Molybdenum (Mo)

• Kα = 17.5 keV
• Kβ = 19.6 keV

K-edge = 20 keV

Rhodium (Rh)

• Kα = 20.2 keV
• Kβ = 22.7 keV

K-edge = 23.3 keV

Image quality

Subject contrast (c) ∝ (μ1 - μ2) x t (μ = attenuation coefficient of object 1 and 2, t = object thickness)

Noise inversely proportional to √photons

Geometric unsharpness (Ug) = f x b / a (f = x-ray focal size; a = distance from x-ray source to front surface of object; b = distance from object to detector)

Magnification (M) = image size / object size = d2 / d1 (d2 = focal spot to detector; d1 = focal spot to object)

Sampling frequency = 2 x Nyquist frequency

Quality assurance

Required by IRR 1999. IPEM report 91 provides guidance.

Equipment tested Frequency of testing Method of testing Performance criteria
X-ray tube output 1-2 months Dose at various exposures measured with ionisation chamber at known distance

Repeatability:

• Remedial = ± 10%
• Suspension = ± 20%

Consistency:

• Remedial = ± 20%
• Suspension = ± 50%
Light beam alignment 1-2 months Light beam field compared to exposed field on film

Remedial = 1 cm misalignment on any side at 1 m from focal spot

Suspension = 3 cm

Automatic exposure control (AEC) performance 1-3 months Film exposed at different tube voltages and different perspex thicknesses to ensure consistent OD

Remedial = ± 0.3 OD relative to baseline

Suspension = ± 0.5 OD relative to baseline

Low contrast sensitivity 4-6 months Uses Leeds Test Object Ltd test object Remedial = baseline ± 2 groups
DR/CR limiting spatial resolution 4-6 months Uses lead grating resolution bar pattern Remedial = baseline minus 25%
AEC ionisation chamber consistency Annual Expose ionisation chambers separately and compare (usually three)

Remedial = ± 0.3 OD relative to baseline

Suspension = ± 0.5 OD relative to baseline

Focal spot Annual

Pinhole

Pinhole radiographed and size, shape and inconsistencies of focal spot calculated from image produced

Star test object

Filtration Annual

Half value thickness / layer of filter determined and compared to available data to calculate filtration

Should be equivalent to 2.5 mm aluminium

Detector dose indicator repeatability and reproducibility Annual

Remedial = baseline ± 10%

Suspension = baseline ± 20%

Threshold contrast detail detectability Annual Test object with appropriate filter and kV imaged
Uniformity of resolution Annual Fine wire mesh imaged Remedial = increase in blurring from baseline
Scaling errors Annual Grid imaged with object of known length Remedial = >2% deviation from object
Dark noise Annual No exposure or low exposure Remedial = baseline + 50%
X-ray tube kV 1-2 years Electronic kV meter measures kV at different exposure settings

Remedial = ±5% or ±5 kV from baseline

Suspension = ± 10% or ± 5kV from baseline

CT imaging

Detector array = 8 - 64 rows; 700 - 900 detectors per row

Single slice pitch = detector pitch = couch travel per rotation / detector width

Multislice pitch = beam pitch = couch travel per rotation / total width of simultaneously acquired slices

Hounsfield unit (HU) = CT number = 1000 x (ut - uw) / uw (ut = attenuation coefficient of tissue; uw = attenuation coefficient of water)

Focal spot: fine = 0.7 mm, broad = 1.0 mm)

Pixel size (d) = FOV / n (FOV = field of view; n = image matrix size)

Highest spatial frequency (fmax) = 1 / 2d

CT number values
Tissue CT number
Bone
Liver
White matter
Grey matter
Intravascular blood
Fresh clotted blood
Muscle
Kidney
CSF
Water
Fat
Air
+1000
40 to 60
20 to 30
37 to 45
40 to 45
70 to 80
10 to 40
30
15
0
-50 to -100
-1000

Dose

Dose = mAs / pitch

Measurement Definition Equation Unit
CT dose index
(CTDI)
Dose to the detector from single gantry rotation   mGy
Weighted CTDI
(CTDIw)
Adjusted for spatial variation of dose ⅓ CTDIcentre + ⅔ CTDIperiphery mGy
Volume CTDI
(CTDIvol)
Accounts for pitch CTDIw / pitch mGy
Dose length product
(DLP)
Total dose along distance scanned CTDIvol x distance scanned mGy cm
Effective dose
(E)
Physical effect of total radiation dose 1) Σ (HT x WT)

2) EDLP x DLP

HT = individual organ dose
WT = tissue weighting factor
EDLP = agreed value of EDLP for whole region

Ultrasound imaging

Equations

Audible range of soundwaves = 20 to 20,000 Hz

Medical ultrasound = 2 to 18 MHz

Velocity (c) = √ ƙ / ρ (ƙ = rigidity; ρ = density)

c = f λ (f = frequency; λ = wavelength)

Speed of sound through tissue = 1540 ms

Intensity (dB ratio) = 10 log10 (I1 / I2) (I1 = intensity 1; I2 = intensity 2)

Acoustic impedence (Z, kg m-2 s-1) = density x speed of sound in that material

Reflection coefficient (R) = Z2 - Z1)2 / Z2 + Z1)2

Beam weight = focal length x λ / D (λ = wavelength; D = diameter of PZT crystals)

Doppler

Resistive index (RI) = (peak systolic frequency - end diastolic frequency) ÷ peak systolic frequency

Pulsatility index (PI) = (peak systolic frequency - minimum frequency) ÷ time averaged maximum frequency

In low resistance artery: normal RI = 0.6 - 0.7; abnormal RI = 0.8 - 1.0

Nyquist limit = PRF / 2

Equipment

Piezoelectric material = ½ wavelength thick; 256 crystals

Matching layer = ¼ wavelength thick

Near field distance = D2 / 4λ (D = diameter of transducer; λ = wavelength)

Pulse repetition frequency (PRF) = frame rate x lines per frame

Distance of wave = time x velocity x 0.5

Depth of view = 0.5 x sound velocity / PRF

Safety

Thermal index (TI) = power emitted / that required to increase temperature by 1°c. Keep < 0.5

Mechanical index (MI) = peak negative pressure / √ultrasound frequency. Keep < 0.7. In fetal scanning <0.5

Time averaged intensity < 100 mWcm-2

Total sound energy < 50 Jcm-2

MR imaging

Equations

Larmor equation (F) = precessional frequency = K x B0 (K = gyromagnetic ration; B0 = strength of static magnetic field)

Larmor frequency of hydrogen at 1 Tesla = 42 MHz

Larmor frequency of hydrogen at 1.5 Tesla = 63 MHz

T1 = time for Mz (longitudinal magnetisation) to recover to 63%

T2 = time for Mxy (transverse magnetisation) to decay to 37%

Relaxation times at 1 Tesla
T1 (ms) T2 (ms)
Fat 250 80
Kidney 550 60
White matter 650 90
Grey matter 800 100
CSF 2000 150
Water 3000 3000
Bone, teeth Very long Very short

Sequence

Spin echo
• 90º RF → 180º RF rephasing pulse at TE/2 → Echo signal at time TE → repeat at TR
• Scan time = TR x no. GPE x NEX (GPE = phase encoding steps; NEX = number of signal averages or slices)
• Turbo spin echo = TR x no. GPE x NEX / ETL (ETL = echo train length)
• T1 weighted: TR determines T1 signal. Short TR
• T2 weighted: TE determines T2 signal. Long TE
• Proton density: minimise T1 with long TR and minimise T2 with short TE
Inversion recovery
• STIR: short TI of 130 ms (TI = time to application of 180º inversion pulse)
• FLAIR: long TI of 2500 ms
• RF pulse of certain flip angle → gradient applied to rephase spins → echo signal at time TE → repeat at TR
• T1 weighted: large flip angle, short TE and short TR
• T2* weighted: small flip angle, long TE and short TR
• T2 weighted: can't achieve
• Proton density = small flip angle, short TE and short TR

MR Spectroscopy

1. Suppress water signal
• CHESS
2. Select voxel / voxels
• Single-voxel spectroscopy (SVS)
• Multi-voxel chemical shift imaging
3. Acquire spectrum
• PRESS and STEAM
Metabolite Frequency (ppm) Role Clinical relevance
mI Myoinositol 3,6 Glial marker

Raised in gliomas and MS

Reduced in herpetic encephalitis

Cho Choline 3,2 Cell membrane and metabolism marker Raised in tumours and demyelination
Cr Creatine 3,0 Energy metabolism marker Constant peak
Glx GABA, glutamine, glutamate 2,1 - 2,5 Intracellular neuronal transmitter Raised in hepatic encephalopathy
NAA N-Acetyl-Aspartate 2,0 Healthy neuronal marker

Raised in Canavan's disease

Reduced in any condition resulting in loss of neurons

Lac Lactate 1,3 doublet Anaerobic respiration Raised in ischaemia, seizures, tumours, mitochondrial disorders
Lip Lipids 0,9 and 1,4   Raised in necrotic tumours
aa Aminoacids 0,97   Raised in pyogenic abscesses

Localisation

1. Slice select along Z-axis with gradient
2. Segment along X-axis selected by frequency encoding
3. Segment along Y-axis selected by phase encoding
4. For 3D, segment along Z-axis selected by phase encoding
5. Wave decoded with Fourier transformation

K-space: periphery for fine detail, centre for contrast information

Angiography

Time of flight (TOF): non-contrast bright blood technique. Uses flow-related enhancement artefact

Phase contrast: non-contrast bright blood technique. Uses spin phase artefact.

Contrast enhanced: IV contrast bright blood technique

Contrast agents:

• T1 paramagnetic = shorten T1 = high T1 signal e.g. gadolinium, hepatobiliary agents that contain manganese
• T2 superparamagnetic = speeds up T2 decay = low T2 signal e.g. iron oxide based SPIOs and USPIOs

Artefacts

Local field inhomogeneity artefacts occur in frequency-encoding direction

External RF signal artefacts occur in phase-encoding direction

Molecular imaging

Non-nuclear molecular imaging

• Contrast-enhanced ultrasound
• Bubbles 1-4 μm
• Filled with high-molecular weight gas e.g. perfuorocarbon and sulphur hexafluoride
• Shell made typically of lipid
• Optical imaging
• Bioluminescence: intracellular luciferase reacts with injected luciferin to produce detectable photon
• Fluorescence: injected molecule activated with external light source and photon emissions released from decay of excited state measured
• MR spectroscopy

• Cyclotron: Technetium-99m (molybdenum target), Fluorine-18 (Oxygen-18 target), Gallium-67, Thallium-201
• Nuclear reactor: Molybdenum (used to make Tc99m), Iodine-131, Xenon-133
Radiopharmaceutical and clinical use Method of decay Method of production Half-life

Carbon-11

C11-choline: prostate PET

C11-L-Methyl-methionine: Brain and parathyroid

Positron Cyclotron 20.3 m

Carbon-14

C14-Glycocholic acid: intestinal overgrowth

C14-Urea: H. pylori

Beta Reactor 5730 y

Chromium-51

Cr51: RBC

Cr51-EDTA: GFR

Gamma Reactor 28 d

Cobalt-57

Co57-Cyanocobalamin: GI absorption

Gamma Cyclotron 279 d

Fluorine-18

F18-FDG: PET

F18-sodium fluoride: bone

F18-Fluorocholine: prostate

F18-Desmothoxyfallypride: dopamine receptor

Positron Cyclotron 109 m

Gallium-67

Ga67-Ga3+: tumour, infection, inflammation

Ga67-Citrate: Hodgkins, inflammation

Gamma Cyclotron 78.3

Gallium-68

Ga68-Dotatoc: neuroendocrine tumour

Ga68-PSMA: prostate

Positron Generator 68 m

Indium-111

In111-DTPA: VP shunt, cisternography

In111-leucocytes: inflammation / infection

In111-platelets: thrombus

In111-Pentetreotide or Octreotide: neuroendocrine tumour

Gamma Cyclotron 1.81 d

Iodine-123

I123-Iodide: thyroid function and mets

I123-MIBG: neuroectodermal tumour

I123-ioflupane aka DaTscan: Parkinsons

Gamma Cyclotron 13.2 h

Iodine-131

I131-Iodide: hyperthyroid, thyroid cancer

I131-MIBG: neuroectodermal tumour

Gamma and beta Reactor 8.06 d

Krypton-81m

K81m-gas: ventilation

K81m-aqueous: lung perfusion

Gamma Cyclotron 13 s

Oxygen-15

O15-water

Positron Cyclotron 2.04 s

Strontium-89

Sr89-Chloride: bone mets

Beta Reactor 50.5 d

Technetium-99m

Tc99m-Pertechnetate: thyroid, stomach, Meckel's, brain

Tc99m-human albumin: blood pool, lung perfusion

Tc99m-Phosphonates: bone, myocardial

Tc99m-DTPA: renal and brain

Tc99m-DTPA: lung ventilation

Tc99m-DMSA: tumour and renal

Tc99m-Colloid: bone marrow, GI bleeding

Tc99m-HIDA: biliary function

Tc99m-denature RBCs: RBC volume, spleen

Tc99m-whole RBCs: GI bleeding, cardiac blood pool

Tc99m-MAG3: renal

Tc99m-HMPOA: cerebral perfusion

Tc99m-examatazime labelled leucocytes: infection / inflammation

Tc99m-Sestamibi: myocardium, parathyroid

Tc99m-TetrofosminL parathryoid, myocardium

Tc99m-Tilmanocept: lymphatic mapping

Gamma Generator 6.02 h

Thallium-201

TI201-Tl: thyroid tumour, parathyroid, myocardium

Gamma Cyclotron 73.5 h

Xenon-133

Xe133-gas: inhalation

Xe133 in isotonic sodium chloride: cerebral perfusion

Gamma Reactor 2.26 d

Equipment

Collimator:

• Low energy = 150 keV = 0.3 mm = 99mTc
• Medium energy = 300 keV = 1 mm = Indium-111
• High energy = 400 keV = 2 mm = 131I

Scintillation crystal: sodium iodide with thallium (NaI(Tl)); 6-13 mm thick

PET imaging

Positron decay → annihilation with electron → two 511 keV photons

Scintillation crystal: bismuth germanate (BSO), lutetium oxyorthosilicate (LSO and gadolinium oxyorthosillicate (GSO)

Image quality

Subject contrast (Cs) = (AL - AT) / AT (AL = activity per unit of lesion; AT = activity per unit mass of healthy tissue)

Image contrast (CI) = (SL - ST) / ST (SL = counts per unit area of lesion; ST = counts per unit area of healthy tissue)

Noise contrast (CN) = 1 / √(AS) (A = area; S = count density)

Collimator spatial resolution (RC) ≈ d (1 + b/h) (d = hole diameter; b = distance from radiation source to collimator; h = hole length)

System spatial resolution (RS) = √(RI2 + RC2) (RI = intrinsic spatial resolution; RC = collimator spatial resolution)

Energy resolution = FWHM (keV) / photopeak energy (keV) x 100 (FWHM = full width half maximum)

Scatter rejection = 20% acceptance window

Dose

Absorbed dose (Gray) = energy deposited per unit mass of tissue

Effective dose (Sievert) = ∑(equivalent dose x tissue weighting factor)

Equivalent dose = ∑(absorbed dose to tissue x radiation weighting factor)

Background radiation = 2.7 mSv/year (2.3 mSv natural sources, 0.4 mSv medical exposure)

X-ray and gamma ray 1
Beta particles and positrons 1
Neutrons < 10 keV 5
Neutrons 100 keV - 2 MeV 20
Alpha particles 20

External radiation: gamma and x-rays > beta > alpha

Internal radiation: alpha > beta > gamma and x-rays

For other dose effects see: Dose effects

Organ Tissue weighting factor
Skin, bone, brain, salivary glands 0.01
Red bone marrow, colon, lung, stomach, breast, remainder of tissues 0.12

Protection

0.25 mm for 100 kV

0.35 mm for 150 kV

Thyroid shields 0.5 mm
Lead glasses 0.25 x 1.0 mm
Modern gloves have 0.5 or 1.0 mm

Legislation

Ionising Radiation (Medical Exposure) Regulations (2017) (IR(ME)R 2017)

• ALARP - as low as reasonably practicable
• Governs all medical and non-medical exposures to patients

• Under Health and Safety at Work Act 1974
• Minimises radiation exposure to employees and members of the public
• Enforced by Health and Safety Executive (HSE)
Effective dose limits per year:
 Radiation workers > 18 years old 20 mSv 100 mSv in any 5 consecutive years, max dose of 50 mSv in any single year Members of public 1 mSv Radiation workers < 18 yo 6 mSv i.e. 3/10 of adult dose Dose limit to abdomen of person of reproductive capacity 13 mSv in any consecutive 3 months Comforters and carers 5 mSv Any other person / member of public (fetus counts as members of the public) 1 mSv Pregnant employees dose to foetus 1 mSv for remainder of pregnancy
Equivalent dose limits per year:
Area Employees and trainees >18 yo Trainees <18 yo Any other person
Lens of the eye 20 mSv 15 mSv 15 mSv
Extremities 500 mSv 150 mSv 50 mSv
Skin 500 mSv 150 mSv 50 mSv
Classified workers

Anyone who is likely to receive:

• Effective dose of > 6 mSv in a year (3/10 of dose limit)
• Equivalent dose of > 3/10 of any dose limit i.e.
• >15 mSv/year to lens
• 150 mSv/year to skin or extremities
Controlled area
• Person likely to receive effective dose of > 6 mSv; 15 mSv to lens; or equivalent dose of >3/10 of any relevant dose limit
• External dose rate exceeds 7.5 mSv/h over working day
• Dose rate < 7.5 mSv/h over working day BUT instantaneous dose rate at any point exceeds 100 mSv/h
Supervised area
• Person working in area likely to receive dose of > 1mSv/yr or equivalent dose of > 1/10 of any relevant dose limit
Diagnostic Reference Levels (DRLs)
Abdomen AP 4 2.5
Chest AP 0.2 0.15
Chest PA 0.15 0.1
Cervical spine (AP and lat)   0.3
Knee (AP and lat) 0.6 0.6
Lumbar spine AP 5.7 1.5
Lumbar spine lat 10 2.5
Pelvis AP 4 2.2
Shoulder AP 0.5
Skull AP/PA 1.8
Skull lat 1.1
Thoracic spine AP 3.5 1.0
Thoracic spine lat 7 1.5

Adult CT CTDI vol per sequence (mGy) DLP per complete examination (mGy cm)
Cervical spine 21 440
Chest 12 610
High-resolution CT chest 4 140
Chest, abdomen and pelvis   1000
CT abdominal angiography 15 1040
CTPA 13 440
Abdomen 14 910
Abdomen and pelvis 15 745
Virtual colonoscopy 11 950
Kidneys, ureter and bladder 10 460
Urogram   170
Coronary CT angiography   170 - 380

Paediatric CT CTD vol per sequence (mGy) DLP per complete examination (mGy cm)
Paeds head: 0-1 y 25 350
Paeds head: >1-5 y 40 650
Paeds head: <5 y 60 860

Adult CT-PET / CT-SPECT CTDI vol per sequence (mGy) DLP per complete examination (mGy cm)
PET half body 4.3 400
SPECT bone scan 4.9 150
SPECT parathryoid 5.6 170
SPECT mIBG / octreotide 5.5 240
SPECT cardiac 21 36
Reporting overexposure:
 Accidental exposure Exposure category Criteria for notification All modalities including therapy < 3 mSv effective dose (adult) < 1 mSv effective dose (child) Unintended exposure Exposure category Criteria for notification Intended dose < 0.3 mSv < 3 mSv (adult) < 1 mSv (child) Intended dose 0.3 to 2.5 mSv < 10x more than intended Intended dose 2.5 to 10 mSv < 25 mSv Intended dose > 10 mSv < 2.5x more than intended Interventional / cardiology No procedural failure AND either: dose ≥ 10x local DRL OR observable deterministic effects excluding transient erythema Radiotherapy pre-treatment planning scans CT planning scan needs to be repeated twice to obtain appropriate data set (i.e. 3 scans in total including the intended scan) Foetal - all modalities Failure in the procedure for making pregnancy enquiries AND resultant foetal dose ≥ 1 mGy Breast feeding infant - nuclear medicine only Failure in procedure AND resultant infant effect dose ≥ 1 mSv

Nuclear medicine

RSA93: governs storage and safe disposal of radioactive materials

MRI safety

MHRA guideline for whole body exposure of patients

• Normal and pregnant 4 Tesla
• Controlled 8 Tesla
• Research no limit Tesla

MHRA guideline for exposure of staff

• < 2 T for whole body
• < 5 T for limbs
• < 0.2 T over 24 hours

Controlled area = 5 Gauss, 0.5 mT boundary

1 SAR = 1 W/kg = whole body temperature rise of 0.5ºc

Localised temperature limits (°c)
Operating mode Rise of body core temperature (°c) Head Trunk Extremities SAR W/Kg
Normal 0.5 38 39 40 2
Controlled 1 38 39 40 4
Restricted 2 39 40 41 > 4

Hearing protection needed at 90 dB

Miscellaneous

Resolution

Imaging modality Resolution
Film screen mammography 15 lp/mm
Digital mammography 5 to 10 lp/mm
Fluoroscopy 1 lp/mm
Direct subtraction angiography 2 lp/mm
Fluoroscopy - flat panel detector 3 lp/mm
CT: transaxial 2 lp/mm
CT: Z-sensitivity 2 to 0.4 lp/mm

Procedure Dose Procedure Dose (mSv)
Abdominal
CT Abdo/pelvis 10 XR lower GIT 3
CT colonography 6 XR upper GIT 6
Barium enema 7 XR pelvis 0.5
CNS
CT head 2 XR cervical spine 0.2
CT spine 6 XR thoracic spine 1.0
CT neck 3 XR lumbar spine 1.5
XR skull < 0.1
Chest
CT chest 7 XR chest 0.1
Cardiac CT 3 Mammography 0.4
Cardiac CTA 12 - 20
Extremities
XR hand / foot 0.005
Nuclear imaging
Brain PET (18F FDG) 14 DEXA 0.001
Brain perfusion (99mTc HMPAO) 9 to 10 Renal MAG3 2
Brain SPECT (99mTc sestamibi) 10 Renal DTPA 2
Bone scan 6 DaTscan brain 6 to 10
Heart stress (99mTc sestamibi) 9.4 V/Q 2.5
Thyroid scan 5 Gastric emptying 1
Whole PET/CT 24

Buy FRCR Physics Notes in paperback or on Kindle and follow us for the latest developments and updates via social media.